InflaRx’s (IFRX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRXFree Report) in a research note issued to investors on Thursday morning, Benzinga reports. The firm currently has a $8.00 price objective on the stock.

InflaRx Stock Performance

Shares of IFRX stock opened at $1.61 on Thursday. The company has a market capitalization of $94.80 million, a PE ratio of -2.06 and a beta of 1.20. InflaRx has a 52-week low of $1.14 and a 52-week high of $4.70. The business’s fifty day moving average is $1.43 and its 200 day moving average is $1.53.

InflaRx (NASDAQ:IFRXGet Free Report) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.05. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $1.76 million. On average, sell-side analysts forecast that InflaRx will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James & Associates grew its stake in shares of InflaRx by 7.9% during the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock valued at $286,000 after buying an additional 12,873 shares during the last quarter. 683 Capital Management LLC lifted its position in InflaRx by 17.5% in the third quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock valued at $7,003,000 after purchasing an additional 350,000 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of InflaRx by 109.4% during the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock valued at $248,000 after purchasing an additional 43,501 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in shares of InflaRx by 18.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company’s stock worth $518,000 after buying an additional 48,944 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in InflaRx by 35.3% during the 3rd quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock valued at $969,000 after buying an additional 84,897 shares during the last quarter. Institutional investors own 42.39% of the company’s stock.

About InflaRx

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

Further Reading

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.